Can nanomedicine deliver drugs precisely to tumor sites?

How does nanomedicine actually find and target a tumor?

Nanomedicine uses two main strategies to get drugs to tumors: passive targeting and active targeting. Passive targeting relies on the fact that tumor blood vessels are often leaky and have poor drainage, so nanoparticles around 100-200 nanometers in size naturally accumulate there—this is called the enhanced permeability and retention (EPR) effect. One study using carbon-based nanoparticles specifically leveraged this EPR effect to improve tumor cellular uptake [3]. Active targeting goes a step further by attaching molecules (ligands) to the nanoparticle surface that bind to receptors overexpressed on cancer cells. For instance, folate-coated chitosan nanoparticles increased drug uptake by rat breast cancer cells 5-6 times compared to nanoparticles without folate, and in mice, the signal from the targeted nanoparticles was substantially higher in tumors than in other organs [1]. Another study used levan, a plant polysaccharide that naturally binds to CD44 receptors on cancer cells, achieving 3.7 times higher tumor accumulation than free dye in mice [8]. These approaches can work together—a nanoparticle can be small enough for passive accumulation and also have a targeting ligand for active binding.

How do these nanoparticles release the drug only at the tumor?

Many nanomedicines are designed to release their drug payload only when they reach the tumor's unique environment, which is often more acidic than healthy tissue. This pH-responsive release is a common and effective strategy. One study created pollen-like silica nanoparticles that released up to 87.5% of their drug at pH 5 (similar to a tumor's acidity), and cell tests showed that almost none of the drug was internalized by normal cells, indicating high specificity [4]. Another system used an acid-cleavable bond to release bradykinin (a vasodilator) only in the acidic tumor milieu, which improved blood flow in tumors by 1.4-1.7 fold and increased accumulation of a standard chemotherapy drug by about 3-fold [2]. Similarly, a carbon-based nanoparticle with a pH-responsive imine bond achieved high drug loading (70.12%) and showed significant anti-tumor effect at a low dose while protecting heart cells from doxorubicin toxicity—cardiomyocyte viability increased by an average of 30.58% compared to free drug [3]. These smart release mechanisms are crucial because they minimize damage to healthy tissues while maximizing the drug's effect at the tumor.

What are the limitations—does it always work perfectly?

Despite promising results, nanomedicine tumor targeting faces significant hurdles. A major review of the field notes that biological barriers and pathophysiological heterogeneity—meaning tumors vary widely in their blood supply, density, and receptor expression—are key bottlenecks that limit how much drug actually reaches cancer cells [6]. For example, erratic blood flow in tumors can obstruct nanomedicine distribution, which is why one study specifically worked to improve blood flow before delivering the drug [2]. Another review highlights that while over 20 cancer nanomedicines are clinically approved, many formulations in development still struggle with issues like immune system clearance and off-target effects [7]. The complexity of the tumor microenvironment—including hypoxia (low oxygen), acidity, and high interstitial pressure—can reduce drug effectiveness and contribute to drug resistance [5]. Additionally, some targeting strategies require complex fabrication that can delay regulatory approval [8]. So while the evidence shows nanomedicine can deliver drugs more precisely than conventional chemotherapy, it is not a magic bullet; effectiveness depends on the tumor type, the nanoparticle design, and overcoming these biological obstacles.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2021 to 2025, 4 from 2024 or later, 7 in Q1 journals, collectively cited 351 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 82 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions